[{"id":"d1239cca-1f3b-42e3-8a2d-a23558678181","acronym":"","url":"https://clinicaltrials.gov/study/NCT02546739","created_at":"2021-01-18T12:19:24.215Z","updated_at":"2024-07-02T16:36:35.576Z","phase":"Phase 1","brief_title":"Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL","source_id_and_acronym":"NCT02546739","lead_sponsor":"Beijing Doing Biomedical Co., Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anti-CD19-CAR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-01-26"}]